Browsing Tag
Suven Life Sciences
6 posts
Suven life sciences reports rapid-acting depression treatment breakthrough with ropanicant in phase-2a trial
Suven Life Sciences’ Ropanicant delivers rapid antidepressant effects in Phase-2a trial for MDD. See the results, safety profile, and what’s next.
Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting
Suven Life Sciences, a clinical-stage biopharmaceutical company focused on the development of novel treatments for Central Nervous System…
Suven Life Sciences announces positive results from Samelisant Phase-2 study
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful…
Suven Life Sciences set to begin samelisant phase 2 trial in narcolepsy
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to…
Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer’s…
Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine)…